ArticleJournal of neurosurgery. Case lessons2025
Anaplastic lymphoma kinase-positive primary CNS anaplastic large cell lymphoma in a pediatric patient: illustrative case.
Article in Journal of neurosurgery. Case lessons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnaplastic lymphoma kinase (ALK)-positive primary CNS anaplastic large cell lymphoma (ALCL) is an extremely rare pediatric malignancy. Its radiological appearance often mimics infectious or glial lesions, complicating diagnosis and delaying treatment. OBSERVATIONS: The authors report the case of a 10-year-old immunocompetent female who presented with absence seizures and vomiting. Brain MRI revealed a left frontal lesion with peripheral contrast enhancement and diffusion restriction, suggestive of a cerebral abscess. She was started on antibiotics and underwent resection. Histopathology confirmed ALK-positive primary CNS ALCL. The patient was treated with NHL-BFM (non-Hodgkin lymphoma-Berlin-Frankfurt-Münster) chemotherapy, the ALK inhibitor lorlatinib, and focal cranial radiotherapy (18 Gy/22 fractions). She remains in complete remission at 18 months. A systematic review of 15 pediatric ALK-positive CNS ALCL cases revealed male predominance, supratentorial location, and inconsistent treatment protocols. Methotrexate-based chemotherapy was most common treatment; the role of radiotherapy and surgery varied. LESSONS: ALK-positive primary CNS ALCL should be considered in the differential diagnosis of pediatric intracranial masses with atypical imaging. Early histological confirmation is essential. While chemotherapy remains central to treatment, targeted therapies and radiation-sparing approaches require further investigation to improve outcomes and reduce long-term morbidity in children. https://thejns.org/doi/10.3171/CASE25522.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.